Speciality materials and chemical company has agreed with ophthalmic medical device company for the supply of
Glaukos will use the VitalDose platform as a component in a micro-invasive intraocular implant, dubbed iDose TR, which will help reduce intraocular pressure in patients with primary open-angle glaucoma or .
The integration of the VitalDose platform is expected to enable the delivery of continuous dosing, which can tackle the problem of patient non-adherence issues.
Celanese ophthalmology global business strategy leader Cyonna Holmes said: 鈥淭he inclusion of our VitalDose Platform in Glaukos鈥� iDose TR therapy furthers our mission to improve patient health in ophthalmology for those living with chronic eye diseases.
鈥淥ur team is excited to support Glaukos as they continue to advance their efforts to bring iDose TR to patients who may need a new glaucoma treatment alternative.鈥�
Celanese offers the VitalDose EVA technology platform for use in various applications, including parenteral, ocular delivery, subcutaneous drug delivery implant, as well as ophthalmic, intravitreal and intraocular.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn February this year, Glaukos submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for iDose TR.
The NDA submission is based on results from two Phase II pivotal clinical studies, which assessed iDose TR.
Both studies achieved the primary efficacy endpoints within three months and showed favourable safety and tolerability profiles over 12 months.
